Our structured approach ensures patients across the state receive equal support regardless of location
'Promising early results' is not the same as a fully tested, approved medicine
It is still an effective obesity treatment and remains an NHS option in specialist weight management services
These symptoms are usually brief and resolve on their own
Food and Drug Administration, GLP-1CVOT GLP-1 1.35.4 LEADER (2016) 6 N=9,340 (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), SUSTAIN-6 (2016) 7 N=3,297 (Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes), EXSCEL (2017) 8 N=14,752 (Exenatide Study of Cardiovascular Event Lowering), BCise HARMONY (2018) 9 N=9,463 (Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus) Eperzan/Tanzeum REWIND (2019) 10 N=9,901 (Researching Cardiovascular Events with a Weekly Incretin in Diabetes
doi: 10.5530/pj.2023.15.193 108